Dianthus Therapeutics DNTH Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Spyre Therapeutics, Inc.SYRE

——

Protagonist TherapeuticsPTGX

——

BridgeBio PharmaBBIO

——

Revenue$396.0K-81.8%

Operating income-$46.5M-40.3%

Net income-$40.8M-38.4%

EPS (diluted)-$0.85-3.7%

Cash & equivalents$627.7M+6,105%

Total debt$1.4M-2.3%

Total equity$1.2B+266%

Total assets$1.2B+258%

Operating cash flow-$28.9M-4.4%

CapEx$10.0K-58.3%

Free cash flow-$28.9M-4.4%

Market cap$4.51B+662%

Operating margin-4,558.4%-9,354pp

Net margin-4,104.8%-7,304pp

FCF margin-3,561.6%-6,956pp

Return on equity-28.6%+3.2pp

Debt / equity0×0.0×

Current ratio29.3×+13.3×

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Dianthus Therapeutics's proceeds from sale and maturity of available for sale securities?: Dianthus Therapeutics (DNTH) reported proceeds from sale and maturity of available for sale securities of $104.63M in Q1 2026.
How has Dianthus Therapeutics's proceeds from sale and maturity of available for sale securities changed year-over-year?: Dianthus Therapeutics's proceeds from sale and maturity of available for sale securities increased by 27.4% year-over-year, from $82.14M to $104.63M.